Renuva Injection for Vocal Cord Paralysis
Trial Summary
What is the purpose of this trial?
This trial is testing Renuva, a fat tissue-based filler, on patients with vocal cord issues. The goal is to see if it can safely and effectively improve their voice by stimulating new tissue growth in the vocal cords. Renuva is similar to fat injections that have been used since 1987 for vocal cord treatments.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Renuva Allograft Adipose Matrix for vocal cord paralysis?
Is Renuva Injection safe for use in humans?
How is the Renuva treatment different from other treatments for vocal cord paralysis?
Renuva is unique because it uses an allograft adipose matrix, which is derived from human fat tissue, to enhance vocal function without the early resorption and morbidity associated with autologous fat injections. This treatment offers greater biostability and avoids the need for liposuction, making it a promising option for stable vocal fold augmentation.1671011
Research Team
Eligibility Criteria
This trial is for adults over 18 with unilateral vocal fold immobility and glottic insufficiency lasting at least two weeks. Participants must consent to follow the study procedures. Pregnant individuals, those with active laryngeal infections or other complex laryngeal conditions, a life expectancy under six months, or allergies to certain anesthetics cannot join.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a unilateral injection augmentation with allograft adipose matrix injectable (Renuva) in the vocal fold
Follow-up
Participants are monitored for safety and effectiveness after treatment, with assessments at 0, 1, 3, 6, 12, and 18 months
Treatment Details
Interventions
- Renuva Allograft Adipose Matrix (Allograft Adipose Injectable)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Southern California
Lead Sponsor
Dr. Samir A.
University of Southern California
Chief Executive Officer since 2024
PhD in Molecular Biology from the University of Southern California
Dr. Chung
University of Southern California
Chief Medical Officer since 2016
MD from UC San Diego